Physician profile
James L Wang
NPI 1124524004
$2,427.46
in general payments reported to CMS, 2019-2025
15 companies · $957 in 2025
The $957 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $490 · 2024: $981 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.59 |
| Education | $139.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $653.66 | 2023-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $537.88 | 2023-2025 | Dalvance, Avycaz, Teflaro |
| Merck Sharp & Dohme LLC | $271.91 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $245.49 | 2023-2025 | Fetroja |
| Gilead Sciences, INC. | $151.54 | 2024-2025 | Sunlenca |
| Cumberland Pharmaceuticals, INC. | $150.95 | 2024-2025 | Vibativ |
| La Jolla Pharmaceutical Company | $128.05 | 2023-2025 | Xacduro, Xerava, Zevtera |
| Neurocrine Biosciences, INC. | $65.85 | 2025 | |
| Melinta Therapeutics, LLC | $50.48 | 2025 | Rezzayo |
| Paratek Pharmaceuticals, INC. | $37.74 | 2024-2025 | Nuzyra |
| Astellas Pharma US INC | $30.71 | 2025 | Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $30.05 | 2025 | Inbrija, Xeomin |
| Aimmune Therapeutics, INC. | $24.95 | 2023 | |
| Ferring Pharmaceuticals INC. | $17.89 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.